bioRxiv preprint doi: https://doi.org/10.1101/513671; this version posted January 7, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Therapeutic potential of inhibition of the neuroinflammation induced cathepsin X: in vivo evidence Anja Pišlar1†*, Larisa Tratnjek2,3†, Gordana Glavan4, Nace Zidar5, Marko Živin2, Janko Kos1,6 1 Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia 2 Institute of Pathophysiology, Medical faculty, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia 3 Institute of Cell Biology, Medical faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia 4 Department of Biology, Biotechnical faculty, University of Ljubljana, Večna pot 11, 1000 Ljubljana, Slovenia 5 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia 6 Department of Biotechnology, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia Running title: Cathepsin X upregulation in the LPS rat model † These authors contributed equally. * Correspondence to: Anja Pišlar, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia, Tel: +386 1 4769526, Fax: +386 1 4258031, E-mail:
[email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/513671; this version posted January 7, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Parkinson’s disease (PD) is a progressive neurodegenerative disorder with unknown cause, but it has been postulated that chronic neuroinflammation may play a role in its pathogenesis.